Systemic lupus erythematosus

Annals of Internal Medicine

Volumn 159, Issue 7, 2013, Pages

  Kiriakidou, Marianthi ^a   Editors, Section ^a   Cotton, Deborah ^a   Taichman, Darren ^a   Williams, Sankey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; BETAMETHASONE; CHLOROQUINE; CLOBETASOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; SALBUTAMOL; TACROLIMUS; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; VASODILATOR AGENT; WART VIRUS VACCINE;

ACNE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; AVASCULAR NECROSIS; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIAC MYOTOXICITY; CARDIOTOXICITY; CATARACT; CLINICAL FEATURE; CUSHINGOID SYNDROME; CUTANEOUS VASCULITIS; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EYE DISEASE; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GLAUCOMA; GONAD DYSFUNCTION; HAIR LOSS; HEART VENTRICLE HYPERTROPHY; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; INFLUENZA; INFLUENZA VACCINATION; INFUSION RELATED REACTION; KIDNEY DISEASE; LABORATORY TEST; LIVER TOXICITY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MIGRAINE; MYALGIA; MYOPATHY; NEOPLASM; NEPHROTOXICITY; NEUROPSYCHIATRY; NEUROTOXICITY; OSTEOPOROSIS; PAPILLOMAVIRUS INFECTION; PERICARDITIS; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PLEUROPERICARDITIS; PNEUMOCOCCAL INFECTION; PREGNANCY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; RETINA DISEASE; SCREENING; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UVEITIS; VASCULITIS;

GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT EDUCATION AS TOPIC; RISK FACTORS;

EID: 84884871568     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-7-201310010-01004     Document Type: Article

References (66)

1. Demas KL, Costenbader KH. Disparities in lupus care and outcomes. Curr Opin Rheumatol. 2009;21:102-9. [PMID: 19339919]
2. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550-7. [PMID: 16868977]
3. Sestak AL, Fürnrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011;70 Suppl 1:i37-43. [PMID: 21339217]
4. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010;6:683-92. [PMID: 21060334]
5. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33. [PMID: 14561795]
6. Seibold JR, Wechsler LR, Cammarata RJ. LE cells in intermittent hydrarthrosis [Letter]. Arthritis Rheum. 1980;23:958-9. [PMID: 6157396]
7. Ball EM, Bell AL. Lupus arthritis--do we have a clinically useful classification? Rheumatology (Oxford). 2012;51:771-9. [PMID: 22179731]
8. Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20:373-85, v. [PMID: 12170873]
9. Alarcón GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus. 1999;8:197-209. [PMID: 10342712]
10. Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13:300-7. [PMID: 21503694]
11. Vilá LM, Alarcón GS, McGwin G Jr, et al; Lumina Study Group. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum. 2006;55:799-806. [PMID: 17013840]
12. Durán S, Apte M, Alarcón GS, et al; Lumina Study Group. Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort. Arthritis Rheum. 2008;59:1332-40. [PMID: 18759263]
13. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21:2028-35. [PMID: 21051743]
14. Cervera R, Khamashta MA, Font J, et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308. [PMID: 14530779]
15. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154-60. [PMID: 23754671]
16. Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31:479-88. [PMID: 20692540]
17. Peponis V, Kyttaris VC, Tyradellis C, et al. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006;15:3-12. [PMID: 16482739]
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [Letter]. Arthritis Rheum. 1997;40:1725. [PMID: 9324032]
19. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86. [PMID: 22553077]
20. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immunemediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007;6:223-35. [PMID: 18220957]
21. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145-53. [PMID: 21221847]
22. Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol. 2012;6:377-83. [PMID: 22457587]
23. Mackworth-Young CG, David J, Morgan SH, et al. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis. 1988;47:496-502. [PMID: 3289511]
24. Albert DA, Hadler NM, Ropes MW. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum. 1979;22:945-53. [PMID: 475873]
25. Edwards JC, Snaith ML, Isenberg DA. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis. 1987;46:773-6. [PMID: 3318723]
26. Badsha H, Kong KO, Lian TY, et al. Lowdose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus. 2002;11:508-13. [PMID: 12220105]
27. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-22. [PMID: 12117678]
28. Da Silva JA. Safety of glucocorticoids-clinical trials. Clin Exp Rheumatol. 2011;29:S99-103. [PMID: 22018193]
29. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275-9. [PMID: 10381042]
30. Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012;15:62-8. [PMID: 22324948]
31. Fortin PR, Abrahamowicz M, Ferland D, et al; Canadian Network For Improved Outcomes in Systemic Lupus. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2008;59:1796-804. [PMID: 19035431]
32. Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549-57. [PMID: 8815753]
33. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-57. [PMID: 11511139]
34. Hochstadt A, Rozman Z, Zandman-Goddard G. [Mycophenolate mofetil as a novel treatment for lupus nephritis]. Harefuah. 2011;150:542-7, 550. [PMID: 21800496]
35. Anderka MT, Lin AE, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241-8. [PMID: 19441125]
36. Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and metaanalysis. Medicine (Baltimore). 2010;89:227-35. [PMID: 20616662]
37. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38:69-78. [PMID: 20952473]
38. Hahn BH, McMahon MA, Wilkinson A, et al; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797-808. [PMID: 22556106]
39. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-80. [PMID: 14999109]
40. Dooley MA, Jayne D, Ginzler EM, et al; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886-95. [PMID: 22087680]
41. Houssiau FA, D'Cruz D, Sangle S, et al; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083-9. [PMID: 20833738]
42. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 2006;1:925-32. [PMID: 17699309]
43. Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20:636-40. [PMID: 21382917]
44. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, doubleblind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222-33. [PMID: 20039413]
45. Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-26. [PMID: 22231479]
46. Andrade-Ortega L, Irazoque-Palazuelos F, López-Villanueva R, et al. [Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study]. Reumatol Clin. 2010;6:250-5. [PMID: 21794725]
47. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-60. [PMID: 19890271]
48. Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004;66:2411-5. [PMID: 15569333]
49. Yap DY, Yu X, Chen XM, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17:352-7. [PMID: 22295934]
50. Chen W, Liu Q, Chen W, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 2012;21:944-52. [PMID: 22438027]
51. Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120-4. [PMID: 10666167]
52. Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol. 2012;2012:854941. [PMID: 22489252]
53. Gonzalez-Lopez L, Cardona-Muñoz EG, Celis A, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus. 2004;13:105-12. [PMID: 14995003]
54. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupusand mixed connective tissue diseaseassociated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521-31. [PMID: 18240255]
55. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1990;20:48-56. [PMID: 2218553]
56. Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol. 2009;23:469-80. [PMID: 19591778]
57. Neumann R, Foster CS. Corticosteroidsparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Retina. 1995;15:201-12. [PMID: 7569347]
58. Furie R, Petri M, Zamani O, et al; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30. [PMID: 22127708]
59. Navarra SV, Guzmán RM, Gallacher AE, et al; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31. [PMID: 21296403]
60. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343-9. [PMID: 22337213]
61. Tseng CE, Buyon JP, Kim M, et al. The effect of moderatedose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2006;54:3623-32. [PMID: 17075807]
62. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72:659-64. [PMID: 22589375]
63. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48:3207-11. [PMID: 14613284]
64. Natekar A, Pupco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011;57:1401-2. [PMID: 22170192]
65. Petri M, Lakatta C, Magder L, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96:254-9. [PMID: 8154514]
66. Gabriel S, Tugwell P, O'Brien B, et al. Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology. J Rheumatol. 1999;26:203-6. [PMID: 9918264]